$VYGR Cashflow Statement | Understand Stock

$VYGR

$1.78 +$0.03 (1.71%) Live

$VYGR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flow from operating activities
Net (loss) income
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Stock-based compensation expense
Depreciation
Impairment charge on leased facility
Gain on lease termination
Change in fair value of common stock and warrants to purchase equity securities
Amortization of premiums and discounts on marketable securities
Loss on disposal of fixed assets
Non-cash lease expense

Changes in operating assets and liabilities:
Accounts receivable
Related party collaboration receivable
Prepaid expenses and other assets
Operating lease, right-of-use assets
Other non-current assets
Accounts payable
Accrued expenses
Operating lease liabilities
Deferred revenue
Net cash (used in) provided by operating activities

Cash flow from investing activities
Purchases of property and equipment
Purchases of marketable securities
Proceeds from sales and maturities of marketable securities
Net cash provided by (used in) investing activities
Cash flow from financing activities
Proceeds from the exercise of stock options
Proceeds from the issuance of common stock and pre-funded warrants in connection with the underwritten public offering
Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement
Proceeds from the purchase of common stock under ESPP
Net cash provided by financing activities
Net (decrease) increase in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash beginning of period
Cash, cash equivalents, and restricted cash end of period
Supplemental disclosure of cash and non-cash activities
Operating lease right-of-use asset obtained in exchange for operating lease liability
Capital expenditures incurred but not yet paid

Comments